RPRX vs DBVT

Royalty Pharma plc (RPRX) offers the better valuation at 27.

9x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Royalty Pharma plc (RPRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Royalty Pharma plc (RPRX) delivered a total return of +32.

4%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: RPRX returned +22. 9% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Royalty Pharma plc (RPRX) is the lower-risk stock at 0.

45β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 177% more volatile than RPRX relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 92% for Royalty Pharma plc — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Royalty Pharma plc grew EPS -5.

8% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Royalty Pharma plc (RPRX) is the more profitable company, earning 32.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 32. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65. 6% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

In this comparison, RPRX (1.

3% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Royalty Pharma plc (RPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 1. 3% yield). Both have compounded well over 10 years (RPRX: +22. 9%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

RPRX pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.